Zeria Pharmaceutical Co., Ltd. logo

Zeria Pharmaceutical Co., Ltd.

4559.T

JPXHealthcareDrug Manufacturers - Specialty & Generic

Latest quote

¥2,122

−¥31.00 · -1.44%

Aug 24, 1:53 PM JSTData delayed

4559.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural and industrial chemicals, and reagents in Japan and internationally. The company operates through Ethical Pharmaceuticals Business and Consumer Healthcare Business segments. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company also offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn’s disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia, and iron deficiency anemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; and non-steroidal anti-inflammatory ophthalmic solutions. In addition, it provides consumer healthcare products, such as nutritional health drugs, remedies for gastrointestinal diseases, western herbal medicines, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, soft drinks/health foods, and food for specified health uses. Further, the company engages in insurance agency and real estate business. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was incorporated in 1955 and is headquartered in Tokyo, Japan.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
JP
CEO
Sachiaki Ibe
Listed since
Jan 1, 2001
Employees
1,748

Market position

Day range

Current ¥2,122

52-week range

Current ¥2,122

Open
¥2,156
Previous close
¥2,153
Volume
72.9K
0.77× average
Average volume
94.78K
Average daily volume
Market cap
93.54B JPY
Beta
0.06
Market reference 1
50-day average
¥2,078.32
+2.10% above average
200-day average
¥2,126.89
-0.23% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
108.1B JPY
P/E (TTM)
11.37×
P/B (TTM)
0.87×
P/S (TTM)
1.03×
EV / EBITDA
5.48×
Earnings yield
8.74%
Free cash flow yield
7.85%
Dividend yield
2.31%

Profitability & efficiency

Gross margin
72.99%
Operating margin
14.05%
Net margin
9.03%
Return on equity
7.80%
Return on assets
4.70%
Return on invested capital
5.89%

Financial health

Debt / equity
0.34×
Current ratio
1.48×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends80%53%27%0%Gross margin, FY2021: 70.80%Gross margin, FY2022: 65.98%Gross margin, FY2023: 66.27%Gross margin, FY2024: 66.55%Gross margin, FY2025: 73.11%Operating margin, FY2021: 10.69%Operating margin, FY2022: 13.18%Operating margin, FY2023: 12.83%Operating margin, FY2024: 13.97%Operating margin, FY2025: 13.88%Net margin, FY2021: 6.65%Net margin, FY2022: 9.06%Net margin, FY2023: 10.21%Net margin, FY2024: 11.38%Net margin, FY2025: 9.48%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 70.80%. Gross margin FY2022 65.98%. Gross margin FY2023 66.27%. Gross margin FY2024 66.55%. Gross margin FY2025 73.11%. Operating margin FY2021 10.69%. Operating margin FY2022 13.18%. Operating margin FY2023 12.83%. Operating margin FY2024 13.97%. Operating margin FY2025 13.88%. Net margin FY2021 6.65%. Net margin FY2022 9.06%. Net margin FY2023 10.21%. Net margin FY2024 11.38%. Net margin FY2025 9.48%.

Income trends

Revenue

89.16B JPY+2.12%

Operating income

12.37B JPY+1.45%

Net income

8.45B JPY-14.91%
Income trends across reported periods97.68B JPY63.6B JPY29.52B JPY−4.56B JPYRevenue, FY2021: 59.53B JPYRevenue, FY2022: 68.38B JPYRevenue, FY2023: 75.73B JPYRevenue, FY2024: 87.31B JPYRevenue, FY2025: 89.16B JPYOperating income, FY2021: 6.37B JPYOperating income, FY2022: 9.01B JPYOperating income, FY2023: 9.72B JPYOperating income, FY2024: 12.2B JPYOperating income, FY2025: 12.37B JPYNet income, FY2021: 3.96B JPYNet income, FY2022: 6.2B JPYNet income, FY2023: 7.73B JPYNet income, FY2024: 9.94B JPYNet income, FY2025: 8.45B JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 59.53B JPY. Revenue FY2022 68.38B JPY. Revenue FY2023 75.73B JPY. Revenue FY2024 87.31B JPY. Revenue FY2025 89.16B JPY. Operating income FY2021 6.37B JPY. Operating income FY2022 9.01B JPY. Operating income FY2023 9.72B JPY. Operating income FY2024 12.2B JPY. Operating income FY2025 12.37B JPY. Net income FY2021 3.96B JPY. Net income FY2022 6.2B JPY. Net income FY2023 7.73B JPY. Net income FY2024 9.94B JPY. Net income FY2025 8.45B JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue89.16B JPY87.31B JPY75.73B JPY68.38B JPY59.53B JPY
Cost of goods sold23.98B JPY29.2B JPY25.54B JPY23.27B JPY17.38B JPY
Gross profit65.18B JPY58.11B JPY50.18B JPY45.12B JPY42.15B JPY
Research and development4.11B JPY3.73B JPY3.46B JPY4.79B JPY
Selling, general, and administrative52.81B JPY41.81B JPY36.74B JPY32.65B JPY30.99B JPY
Operating expenses52.81B JPY45.91B JPY40.46B JPY36.1B JPY35.78B JPY
Interest income111.81M JPY282.87M JPY150.94M JPY67.89M JPY17.24M JPY
Interest expense501.8M JPY452.29M JPY457.8M JPY337.28M JPY315.46M JPY
Depreciation and amortization7.35B JPY7.55B JPY7.56B JPY6.15B JPY5.4B JPY
Operating income12.37B JPY12.2B JPY9.72B JPY9.01B JPY6.37B JPY
Net income8.45B JPY9.94B JPY7.73B JPY6.2B JPY3.96B JPY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
19.65

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates92.3365.7139.0912.47Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 6, 2024: actual 41.94, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 5, 2025: actual 49.12, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 8, 2025: actual 38.79, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 5, 2025: actual 24.75, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 5, 2025: actual 14.67, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 5, 2026: actual 86.58, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 8, 2026: actual 65.8, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 6, 2026: actual 19.65, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates26.09B23.55B21.02B18.49BQ1 '25No estimateQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 22.35B JPY, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 8, 2025: actual 22.54B JPY, estimate 21.73B JPY, surprise +3.73%, Beat. Q3 2025, reported Aug 5, 2025: actual 19.49B JPY, estimate 22.75B JPY, surprise -14.33%, Miss. Q4 2025, reported Nov 5, 2025: actual 20.47B JPY, estimate 22.15B JPY, surprise -7.58%, Miss. Q1 2026, reported Feb 5, 2026: actual 24.12B JPY, estimate 23.77B JPY, surprise +1.46%, Beat. Q2 2026, reported May 8, 2026: actual 25.08B JPY, estimate 23.92B JPY, surprise +4.84%, Beat. Q3 2026, reported Aug 6, 2026: actual 21.45B JPY, estimate 21.6B JPY, surprise -0.70%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate 22.4B JPY, surprise —, Comparison unavailable.

4559.T peers

ETFs holding 4559.T

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 4559.T

research.disclaimer